Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789

Status:
Completed
Trial end date:
2017-10-15
Target enrollment:
Participant gender:
Summary
This Phase 1 clinical study is a double-blind, randomized, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics (PK), food effect, and drug interaction potential of ACHN-383 and ACHN-789 co-administered orally as separate capsules in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Achaogen, Inc.